- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Johnson & Johnson (JNJ)
Find all the information about Johnson & Johnson stock. Discover our multiple sections with data on JNJ share price, intuitive charts, historical data, technical analysis, latest news on JNJ stock and more.
NYSE
Symbol | Exchange | Currency | |||
|---|---|---|---|---|---|
| JNJ | · | NYSE | · | USD | |
| JNJ | · | Xetra | · | EUR | |
| JNJ | · | Switzerland | · | CHF | |
| 1JNJ | · | Milan | · | EUR | |
| JNJ | · | Vienna | · | EUR | |
| DJNJ2m | · | Buenos Aires | · | ARS | |
| DJNJ3m | · | Buenos Aires | · | ARS | |
| JNJm | · | Buenos Aires | · | ARS | |
| JNJB34 | · | B3 | · | BRL | |
| JNJ | · | Toronto | · | CAD | |
| JNJ | · | Mexico | · | MXN | |
| JNJCO | · | Colombia | · | COP | |
| JNJUS | · | Lima | · | USD | |
| JNJ | · | Ukraine | · | UAH | |
| JNJ | · | Frankfurt | · | EUR | |
| JNJ | · | TradeGate | · | EUR | |
| JNJ_KZ | · | KASE | · | USD | |
| JNJ | · | CBOE Canada | · | CAD |
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
254.42
260.20
52 wk Range
164.23
269.43
JNJ is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
254.42260.20
52 wk Range
164.23269.43
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.07%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.07%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JNJ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
270.59
Upside
+4.37%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
10 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
16 Buy
6 Hold
1 Sell
Ratings:
23 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 270.59
(+4.37% Upside)
Johnson & Johnson SWOT Analysis
Oncology Powerhouse | Johnson & Johnson's oncology division emerges as a key growth driver, with CARVYKTI leading the charge and projections of $50 billion in oncology sales by 2030 |
Financial Resilience | Despite challenges, J&J reports robust Q4 2024 results with 5.9% adjusted operational sales growth, surpassing expectations and demonstrating financial stability |
Strategic Expansion | J&J explores CAR-T therapies beyond oncology, venturing into autoimmune diseases and strengthening its portfolio through strategic acquisitions like V-Wave |
Analyst Perspectives | Price targets range from $152 to $215, reflecting varied outlooks on J&J's growth potential amid ongoing talc litigation and upcoming Stelara biosimilar competition |
Johnson & Johnson Earnings Call Summary for Q2/2026
- J&J reported Q2 2026 adjusted EPS of $2.90 on revenue of $25.31B, beating estimates of $2.86 and $25.02B; shares rose 0.12% to $254.15 in premarket.
- Company raised full-year outlook, projecting $100.6B in sales (6.5-7.1% growth) and adjusted EPS of $11.50-$11.65, targeting $100B+ revenue milestone.
- Innovative Medicine sales grew 6.8% to $16.4B led by TREMFYA, DARZALEX, and new launches; MedTech rose 3.6% to $8.9B despite Abiomed and electrophysiology pressure.
- STELARA biosimilar competition created 460-basis-point headwind; Abiomed sales fell 2% due to physician caution following U.K. study on heart recovery devices.
- CEO Duato emphasized portfolio strength with 28 products generating $1B+ annually; CFO Wolk expects double-digit growth by decade's end with $21B free cash flow.
Last Updated: 15/07/2026, 11:52 pm
Read Full TranscriptEarnings
Latest Release
15/07/2026
EPS / Forecast
2.90 / 2.86
Revenue / Forecast
25.31B / 25.02B
Compare JNJ to Peers and Sector
Metrics to compare | JNJ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJNJPeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.7x | 25.0x | −0.3x | |
PEG Ratio | −3.81 | 0.08 | 0.00 | |
Price/Book | 7.7x | 4.0x | 2.6x | |
Price / LTM Sales | 6.4x | 4.5x | 3.0x | |
Upside (Analyst Target) | 5.7% | 0.0% | 55.4% | |
Fair Value Upside | Unlock | 9.4% | 8.8% | Unlock |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the J&J (JNJ) Stock Price Today?
The J&J stock price today is 259.27 USD.
What Stock Exchange Does J&J Trade On?
J&J is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for J&J?
The stock symbol for J&J is "JNJ."
Does J&J Pay Dividends? What’s The Current Dividend Yield?
The J&J dividend yield is 2.07%.
What Is the J&J Market Cap?
As of today, J&J market cap is 624.12B USD.
What Is J&J's Earnings Per Share (TTM)?
The J&J EPS (TTM) is 8.63.
When Is the Next J&J Earnings Date?
J&J will release its next earnings report on 20/10/2026.
From a Technical Analysis Perspective, Is JNJ a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has J&J Stock Split?
J&J has split 6 times.
How Many Employees Does J&J Have?
J&J has 138200 employees.
What is the current trading status of J&J (JNJ)?
As of 24/07/2026, J&J (JNJ) is trading at a price of 259.27 USD, with a previous close of 259.27 USD. The stock has fluctuated within a day range of 254.42 USD to 260.20 USD, while its 52-week range spans from 164.23 USD to 269.43 USD.
What Is J&J (JNJ) Price Target According to Analysts?
The average 12-month price target for J&J is 270.59 USD, with a high estimate of 305 USD and a low estimate of 190 USD. 16 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +4.37% Upside potential.
What Is the JNJ After Hours Price?
JNJ's last after hours stock price is 260.28 USD, the stock has decreased by 1.01, or 0.39%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.